SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million

Company Overview - SERB Pharmaceuticals is a global specialty pharmaceutical company with a focus on emergency care and rare diseases, boasting the broadest antidote portfolio for chemical, biological, radiological, and nuclear (CBRN) risks [6][9] - The company has over 30 years of experience in treating complex and life-threatening conditions, supporting healthcare systems and governments while providing hope to patients and their families [6] Acquisition Details - SERB Pharmaceuticals announced the acquisition of RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc. for an up-front payment of approximately $75 million, with an additional$5 million milestone payment [8] - As part of the acquisition, SERB will operate the leased manufacturing facility in Hattiesburg, Mississippi, and several employees supporting the RSDL® product will join SERB [8] Product Information - RSDL® is a medical device designed to remove or neutralize chemical warfare agents from the skin, with FDA clearance and over 20 years of clinical data supporting its efficacy [1][3] - The product has sold over 15 million packets across more than 30 countries, highlighting its global reach and acceptance [1] Strategic Importance - The acquisition of RSDL® enhances SERB's position as a leading provider of medical countermeasures for CBRN threats, creating new opportunities for collaboration with governments, militaries, NGOs, and emergency preparedness agencies worldwide [9]